Article
Cardiac & Cardiovascular Systems
Jie Peng, Cathleen Y. Xing, Ketong Zhao, Jingti Deng, Daiana Alvarez Olmedo, Zhiyong Ma, Mingxiang Zhang, Ying Wang
Summary: This study suggests that elevated levels of PCSK9 may contribute to the development of coronary artery disease (CAD), particularly in cases with a higher degree of coronary artery stenosis.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Vittoria Cammisotto, Francesco Baratta, Paola G. Simeone, Cristina Barale, Enrico Lupia, Gioacchino Galardo, Francesca Santilli, Isabella Russo, Pasquale Pignatelli
Summary: PCSK9 is involved in cholesterol metabolism and plays a role in the development of atherosclerosis and atherothrombotic processes, promoting plaque formation and oxidative stress.
Article
Cardiac & Cardiovascular Systems
Alex K. K. Leung, Yuan Chao Xue, Antyrah de Guzman, Guilherme Grzelkovski, HyeJin Julia Kong, Kelly R. Genga, James A. Russell, John H. Boyd, Gordon A. Francis, Keith R. Walley
Summary: This study found that PCSK9 reduces the uptake of LPS in vascular endothelial cells through LDLR-mediated endocytosis, leading to a decrease in the inflammatory response. This suggests that PCSK9 inhibition may have additional effects on vascular endothelial inflammation.
Article
Medical Laboratory Technology
Antonin Jabor, Tereza Vackova, Zdenek Kubicek, Jitka Komrskova, Marek Protus, Janka Franekova
Summary: The study evaluated the biological variation of serum PCSK9, finding a high within-subject variability in healthy individuals, suggesting that common reference intervals can be used to interpret its values.
CLINICA CHIMICA ACTA
(2021)
Article
Pharmacology & Pharmacy
Rabia Aydogan Baykara, Pinar Diydem Yilmaz, Mevlut Hakan Goktepe, Cengiz Kadiyoran, Mustafa Ogul, Adem Kucuk, Medine Cumhur Cure, Erkan Cure
Summary: There is a strong independent association between subclinical atherosclerosis and PCSK9 in patients with Behcet's disease. However, there may be no independent association between PCSK9 and disease activity.
CLINICAL AND EXPERIMENTAL HYPERTENSION
(2022)
Article
Oncology
Beili Xu, Shuyu Li, Yong Fang, Yanting Zou, Dongqiang Song, Shuncai Zhang, Yu Cai
Summary: This study demonstrates that high expression of PCSK9 in gastric cancer tissues is associated with tumor progression and poor prognosis. PCSK9 promotes gastric cancer metastasis and suppresses apoptosis through facilitating the MAPK signaling pathway via upregulation of HSP70. PCSK9 may serve as a potential therapeutic target in gastric cancer.
FRONTIERS IN ONCOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Yimo Zhou, Weiqi Chen, Meng Lu, Yongjun Wang
Summary: This meta-analysis found a significant association between high circulating PCSK9 concentration and the risk of MACEs, with a linear dose-response relationship observed. However, no significant correlation was found with stroke or all-cause mortality. Further well-designed studies are needed to explore the relationships between PCSK9 concentration and stroke and mortality.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Review
Cardiac & Cardiovascular Systems
Jiahui Liu, Fangfang Fan, Xingyu Luo, Wenjun Ji, Yaokun Liu, Yan Zhang, Bo Zheng
Summary: The study found a significant positive correlation between high PCSK9 concentrations and increased risk of cardiovascular events, especially in stable CVD patients, patients on statin therapy, and Asian patients.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Environmental Sciences
Anna Bizon, Grzegorz Franik, Pawel Madej
Summary: This study found significantly higher PCSK9 concentration and lower high-density lipoprotein concentration in the serum of women with PCOS compared to those without, as well as significant differences in paraoxonase 1 activities. Higher PCSK9 concentration in women with PCOS, especially those with insulin resistance, may be associated with hormonal concentrations. The study suggests that changes in paraoxonase 1 activities and lipid profile parameters in women with PCOS could be linked to metabolism disorders, but further research is needed due to the small sample size.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
(2021)
Article
Endocrinology & Metabolism
Ga Eun Lee, Jinjoo Kim, Jihei Sara Lee, JaeSang Ko, Eun Jig Lee, Jin Sook Yoon
Summary: The research revealed a significant role of PCSK9 in the pathogenesis of Graves' orbitopathy (GO), with PCSK9 inhibition attenuating pro-inflammatory cytokine production, oxidative stress, and fibroblast differentiation into adipocytes, suggesting PCSK9 as a potential therapeutic target and biomarker for GO.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Na-Qiong Wu, Hui-Wei Shi, Jian-Jun Li
Summary: PCSK9, in addition to lowering LDL-C levels, also plays a role in the modulation of inflammation, which may explain its reduction in cardiovascular risk. Previous studies have shown that PCSK9 is associated with inflammation, as it can induce inflammatory responses, regulate the expression of inflammatory cytokines, and interact with receptors of inflammatory mediators. The interaction between PCSK9 and LOX-1 may be involved in the inflammatory response of atherosclerosis. Understanding the relationship between PCSK9 and inflammation is crucial for the prevention and management of ASCVD.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Genetics & Heredity
Isabela Bensenor, Kallyandra Padilha, Isabella Ramos Lima, Raul Dias Santos, Gilles Lambert, Stephane Ramin-Mangata, Marcio S. Bittencourt, Alessandra C. Goulart, Itamar S. Santos, Jose G. Mill, Jose E. Krieger, Paulo A. Lotufo, Alexandre C. Pereira
Summary: Pharmacological inhibition of PCSK9 is a known treatment for hypercholesterolemia, and this study identified genetic variants outside the PCSK9 gene that may modulate PCSK9 levels, potentially impacting cardiovascular disease treatment targets. The genetic variation at the PCSK9 locus explained only a small portion of the overall interindividual variations in PCSK9 levels, suggesting the importance of investigating both environmental and genetic predictors for a more comprehensive understanding.
FRONTIERS IN GENETICS
(2021)
Article
Clinical Neurology
Ayako Kunimura, Yuichiro Yano, Takashi Hisamatsu, Sayuki Torii, Keiko Kondo, Aya Kadota, Akira Fujiyoshi, Tomonori Okamura, Yoshiyuki Watanabe, Akihiko Shiino, Kazuhiko Nozaki, Hirotsugu Ueshima, Katsuyuki Miura
Summary: This study investigated the association between serum PCSK9 levels and subclinical cerebrovascular disease in a community-dwelling Japanese male population. The results showed that higher levels of circulating PCSK9 were significantly associated with an increased prevalence of intracranial artery stenosis, but not with cerebral small vessel disease. Therefore, measuring serum PCSK9 levels may help identify individuals at high risk for cerebrovascular disease in the general population.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Biochemistry & Molecular Biology
Po-Wei Chen, Shih-Ya Tseng, Hsien-Yuan Chang, Cheng-Han Lee, Ting-Hsing Chao
Summary: The study reveals that Cilostazol can regulate the expression of PCSK9 through enhancing the PPARγ pathway, thus impacting cholesterol homeostasis. It was observed that Cilostazol significantly reduces PCSK9 levels in high-fat diet-induced obese mice and obese patients, indicating its therapeutic potential for obesity-related dyslipidemia.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biotechnology & Applied Microbiology
Zhenxian Li, Haimei Zhu, Hao Liu, Dayue Liu, Jianhe Liu, Jiazheng Jiang, Yi Zhang, Zhang Qin, Yijia Xu, Yuan Peng, Bin Liu, Yun Long
Summary: In this study, a biomimetic nanoliposome loaded with Evolocumab (a PCSK9 inhibitor) was developed using nano-materials to alleviate atherosclerosis. The results showed that this nanoliposome can inhibit the phenotypic transition, excessive proliferation, and migration of VSMCs. Additionally, it significantly decreased the expression of PCSK9 in serum and VSMCs within the plaque of ApoE(-/-) mice.
JOURNAL OF NANOBIOTECHNOLOGY
(2023)
Article
Endocrinology & Metabolism
Ying Du, Sheng-Hua Yang, Sha Li, Xi Zhao, Yan Zhang, Di Sun, Cheng-Gang Zhu, Na-Qiong Wu, Yuan-Lin Guo, Rui-Xia Xu, Ping Qing, Ying Gao, Jing Sun, Jian-Jun Li
ANNALS OF NUTRITION AND METABOLISM
(2018)
Article
Cardiac & Cardiovascular Systems
Sheng-Hua Yang, Rui-Xia Xu, Chuan-Jue Cui, Yin Wang, Ying Du, Zhi-Guo Chen, Yu-Hong Yao, Chun-Yan Ma, Cheng-Gang Zhu, Yuan-Lin Guo, Na-Qiong Wu, Jing Sun, Bu-Xing Chen, Jian-Jun Li
CARDIOVASCULAR DIABETOLOGY
(2018)
Article
Peripheral Vascular Disease
Hui-Hui Liu, Ye-Xuan Cao, Sha Li, Yuan-Lin Guo, Cheng-Gang Zhu, Na-Qiong Wu, Ying Gao, Qiu-Ting Dong, Xi Zhao, Yan Zhang, Di Sun, Jian-Jun Li
Article
Medical Laboratory Technology
Di Sun, Bing-Yang Zhou, Xi Zhao, Sha Li, Cheng-Gang Zhu, Yuan-Lin Guo, Ying Gao, Na-Qiong Wu, Geng Liu, Qian Dong, Jian-Jun Li
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2018)
Article
Medical Laboratory Technology
Qiu-Ting Dong, Ying Gao, Na-Qiong Wu, Yuan-Lin Guo, Cheng-Gang Zhu, Sha Li, Hui-Hui Liu, Ye-Xuan Cao, Hui-Wen Zhang, Xi Zhao, Geng Liu, Qian Dong, Jian-Jun Li
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2018)
Article
Endocrinology & Metabolism
Di Sun, Sha Li, Xi Zhao, Na-Qiong Wu, Cheng-Gang Zhu, Yuan-Lin Guo, Ying Gao, Ping Qing, Chuan-Jue Cui, Geng Liu, Jing Sun, Qian Dong, Jian-Jun Li
METABOLISM-CLINICAL AND EXPERIMENTAL
(2018)
Article
Cardiac & Cardiovascular Systems
H-W Zhang, X. Zhao, Y-L Guo, Y. Gao, C-G Zhu, N-Q Wu, J. J. Li
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
(2018)
Article
Pharmacology & Pharmacy
Bing-Yang Zhou, Xiong-Yi Gao, Xi Zhao, Ping Qing, Cheng-Gang Zhu, Na-Qiong Wu, Yuan-Lin Guo, Ying Gao, Geng Liu, Qian Dong, Jian-Jun Li
PERSONALIZED MEDICINE
(2018)
Article
Multidisciplinary Sciences
Sha Li, Hui-Wen Zhang, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Xi Zhao, Di Sun, Xiong-Yi Gao, Ying Gao, Yan Zhang, Ping Qing, Xiao-Lin Li, Jing Sun, Geng Liu, Qian Dong, Rui-Xia Xu, Chuan-Jue Cui, Jian-Jun Li
SCIENTIFIC REPORTS
(2018)
Article
Cardiac & Cardiovascular Systems
Ye-Xuan Cao, Hui-Hui Liu, Di Sun, Jing-Lu Jin, Rui-Xia Xu, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Sha Li, Yan Zhang, Jing Sun, Jian-Jun Li
Meeting Abstract
Cardiac & Cardiovascular Systems
Jinglu Jin, Yuanlin Guo, Naqiong Wu, Chenggang Zhu, Ying Gao, Qiuting Dong, Huiwen Zhang, Di Sun, Geng Liu, Qian Dong, Jianjun Li
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2018)
Meeting Abstract
Cardiac & Cardiovascular Systems
Di Sun, Bingyang Zhou, Sha Li, Yuanlin Guo, Naqiong Wu, Chenggang Zhu, Ying Gao, Chuanjue Cui, Geng Liu, Jianjun Li
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2018)
Article
Medical Laboratory Technology
Jun Wen, Qian Dong, Geng Liu, Ying Gao, Xiao-Lin Li, Jing-Lu Jin, Jian-Jun Li, Yuan-Lin Guo
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2020)
Review
Cardiac & Cardiovascular Systems
Ze-Ping Wang, Ya-Jie Wu, Ying Gao, Jie Qian, Long-Tao Liu, Yuan-Lin Guo, Jian-Jun Li, Ke-Ji Chen
Summary: Two siblings with familial hypercholesterolemia (FH) showed clinical phenotypic differences in cardiovascular manifestations, despite having similar LDL-C levels. The proband had more severe stenosis and smaller LDL particle size compared to his elder sister. This highlights the potential role of LDL particle size as a novel indicator for predicting the prognosis of FH.
BMC CARDIOVASCULAR DISORDERS
(2023)
Meeting Abstract
Geriatrics & Gerontology
Q. T. Dong, Y. Zhang, S. Li, Y. Gao, C. G. Zhu, N. Q. Wu, Y. L. Guo, Q. Dong, G. Liu, J. J. Li
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2018)